BSE
MARKET ANALYSIS NEWS CORPORATE INFORMATION CORPORATE ACTIONS OTHER MARKETS
Your Result on : Company News Details
Natco Pharma Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
524816
ISIN Demat
INE987B01026
Book Value (Rs)
461.79599
NSE Symbol
NATCOPHARM
Divident Yield %
0.73
Market Cap
(Rs In Cr.)
14,725
P/E (TTM)
9.7
EPS (TTM)
84.75
Face Value
(Rs)
2
Back
Natco Pharma receives CDSCO approval for launch of Semaglutide in India
14-Feb-26   Hrs IST

Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)